磨玻璃影成分对≤3cm含微乳头/实性病理亚型浸润性腺癌的保护作用
该回顾性研究纳入547例在上海胸科医院行肺叶切除术的浸润性腺癌(≤3cm)患者,按微乳头/实性病理亚型(MP/S)和实性成分占比(CTR=0.5)分为4组。结果显示,CTR-结节中MP/S病理不影响RFS或OS,而CTR+结节中MP/S与更差RFS相关;GGO成分可能是MP/S阳性患者的保护因素。
要点
- CTR-结节中,MP/S病理亚型不影响RFS(P=0.27)和OS(P=0.50)。
- CTR+结节中,MP/S病理亚型与更差RFS相关(P<0.001)。
- 4组5年RFS分别为98%、94%、76%、67%(P<0.001)。
核心结论
- GGO成分可能是≤3cm含微乳头/实性病理亚型浸润性腺癌行肺叶切除术患者的保护因素。
主要发现
- MP/S-CTR-组173例(31.6%),3例复发,2例死亡;MP/S-CTR+组178例(32.5%),10例复发,6例死亡。
- MP/S+CTR-组42例(7.7%),10例复发,9例死亡;MP/S+CTR+组154例(28.2%),51例复发,37例死亡。
- 中位随访66个月(95%CI,52-78个月)。
- 4组5年RFS分别为98%、94%、76%、67%(P<0.001);5年OS分别为99%、97%、79%、76%(P<0.001)。
- CTR-结节中MP/S病理不影响RFS(P=0.27)或OS(P=0.50);CTR+结节中MP/S病理与更差RFS相关(P<0.001)。
关键数值与推荐
- 按MP/S病理亚型有无和CTR=0.5将浸润性腺癌分为4组:MP/S-CTR-、MP/S-CTR+、MP/S+CTR-、MP/S+CTR+。
临床怎么用
- 该发现可能有助于更准确评估复发风险,并为确定此类患者的辅助治疗策略提供指导。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Micropapillary and solid pathological patterns are known to correlate with poor prognosis in invasive adenocarcinoma (IAC). Meanwhile, ground-glass opacity (GGO) components have been identified as a protective factor in IAC. This study investigated the prognostic significance of GGO component in IAC ≤3 cm with micropapillary/solid (MP/S) pathological patterns. METHODS: We retrospectively enrolled 547 patients who underwent lobectomy at Shanghai Chest Hospital between June 1, 2014, and December 31, 2016, with 74 recurrence events and 54 death events observed during follow-up. Invasive adenocarcinoma was classified into 4 groups according to the presence of MP/S pathological patterns and a consolidation-to-tumour ratio (CTR) of 0.5: MP/S-CTR-, MP/S-CTR+, MP/S+CTR-, and MP/S+CTR+. Kaplan-Meier estimator with log-rank test was used to compare overall survival (OS) and recurrence-free survival (RFS) among these 4 subgroups. Cox regression models were applied to identify factors influencing survival. RESULTS: The distribution of the enrolled patients was as follows: MP/S-CTR- type(173 cases, 31.6%, 3 recurrences, 2 deaths); MP/S-CTR+ (178 cases, 32.5%, 10 recurrences, 6 deaths); MP/S+CTR-(42 cases, 7.7%, 10 recurrences, 9 deaths); and MP/S+CTR+(154 cases, 28.2%, 51 recurrences, 37 deaths). The median follow-up time was 66 months (95% CI, 52-78 months). The 5-year RFS rates were 98%, 94%, 76%, and 67%, respectively (P < 0.001). The 5-year OS rates were 99%, 97%, 79%, and 76% for the 4 groups, respectively (P < 0.001). For CTR- nodules, the presence of MP/S pathological patterns did not affect RFS (P = 0.27) or OS (P = 0.50). However, in CTR+ nodules, MP/S pathological patterns was associated with worse RFS (P < 0.001). CONCLUSIONS: The GGO component may be a protective factor for patients who underwent lobectomy for invasive adenocarcinoma ≤3 cm with micropapillary or solid pathological patterns. This finding may contribute to a more accurate assessment of recurrence risk and provide guidance for determining adjuvant strategies in such patients.
引用
- Xu Y, Wang Z, Tao Y, et al. Ground-Glass Opacity Component as a Protective Factor for Patients With Invasive Adenocarcinoma ≤3 cm With Micropapillary or Solid Pathological Patterns. Eur J Cardiothorac Surg. 2025. PMID: 40880299. doi:10.1093/ejcts/ezaf285
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。